LifeArc

ICYMI: A new round of funding for antimicrobial resistance innovators has opened through PACE-AMR. The round closes 5 November, supporting new therapeutics for serious bacterial infections that pose the greatest risk to human health. Link to apply in the comments! https://lnkd.in/e_qgrsYs

Antimicrobial resistance (AMR) is often called the silent pandemic but for those of us in working in this space, we are all too aware that millions of lives are already being lost and that the numbers continue to rise. This week, the World Health Organization released a stark insight into the scale of the crisis: in 2023, 1 in 6 laboratory-confirmed bacterial infections globally were resistant to antibiotics. For infections like UTIs, it was 1 in 3. The report also highlights the growing threat of gram-negative bacteria and the disproportionate impact on low-resource settings. The take home is clear. Our work has never been more important. We must accelerate and expand our efforts to reverse this trend. Read our full response: https://lnkd.in/e5xp-JjR

A warm welcome to our 2025 to 2026 cohort of industrial placement students! This year, students are joining our teams across data science, molecular and cellular pharmacology, analytics, and more, contributing to a diverse range of projects and bringing fresh ideas, energy, and creativity to our work. We're proud to support the next generation of scientists, helping them develop their skills and make an impact early in their careers. Amelie Coy, Cian Swede, Gina Paulo Pereira, Grace McGee, Emilee Alderman, Katie Lawler

In August this year, the FDA approved the first self-injectable version of lecanemab (Leqembi) to treat early Alzheimer’s disease. This means patients can administer the treatment at home without the need to travel to a clinic or hospital. This innovation was recently selected as one of TIME Magazine’s inventions of 2025. This is a significant breakthrough in the future of Alzheimer's and similar diseases, and we are proud of our contribution to the humanisation of lecanemab. However, early diagnosis remains a crucial challenge. This is why we are supporting innovative research of partners like the UK Dementia Research Institute, Our Future Health UK, and Global Alzheimer's Platform Foundation to improve early detection and intervention in Alzheimer’s and rare dementias. https://lnkd.in/eYdgmV9G

Since 2019, we have collaborated with Cleveland Clinic on impactful research initiatives. Together, we have now identified new research areas of mutual interest, including antibody discovery initiatives, and continuous education for clinician scientists. We hope that our partnership will continue to progress innovations that benefit patients worldwide.

Our Head of Childhood Cancer at LifeArc, David Jenkinson, reflects on the transformative potential CAR T-cell therapies could have for children with cancer. CAR T-cell therapies train infection-fighting white blood cells to seek out and kill cancer cells. By targeting specific proteins on cancer cells, these therapies offer a highly precise treatment. Many genetic and biological factors have long posed significant hurdles to progress. However, "the research community is starting to find ways to break through these barriers," says David. "There's real excitement about CAR T-cells for children with cancer." Read more from David as he explores the importance of embracing innovation and adopting new approaches if we are to bring these life-changing therapies to children who need them: https://lnkd.in/er3HanCH

The Innovation Hubs for Gene Therapies are now offering 3 new online training courses created by NHS Blood and Transplant, The University of Sheffield and UCL. These flexible, self-paced courses provide an excellent opportunity for researchers working in the field of gene therapy to gain valuable insights into the development and manufacture of: - Advanced Therapy Medicinal Products (ATMPs) - Gene Therapy Medicinal Products (GTMPs) - Gene Therapy Bioprocessing Each course encompasses a variety of learning materials that cover translational development, including study design, development processes and key regulatory considerations. The Innovation Hubs for Gene Therapy are an £18 million national network, created as part of our partnership with the Medical Research Council and THE BIOTECHNOLOGY AND BIOLOGICAL SCIENCES RESEARCH COUNCIL, to support and accelerate research into new treatments for patients. Learn more about the courses: https://lnkd.in/eG2s-czu

The UK Dementia Research Institute Translation Award Programme provides UK DRI researchers with the opportunity to secure funds for pre-clinical analysis, drug target validation, or other work directly related to finding treatments. We are proud to be supporting 5 projects as part of the fifth round of the Translation Awards – with a commitment of £1.38 million to these important areas of research. Our strategic partnership with UK DRI aims to tackle neurodegenerative diseases and transform early-stage discovery into tests, therapies and treatments that have the highest potential for clinical impact. Marc Aurel Busche Marc-David Ruepp @sarah-mizielinska Sarah Tabrizi, MD PhD FMedSci FRS @vincent-dion @nathan skene

One week ago, over 300 researchers, funders and innovators gathered at #GAMRIC2025 to discuss how we tackle the global crisis of antimicrobial resistance. These are the major takeaways from the 3-day event: • AMR needs global action alongside region-specific strategies that reflect local needs and healthcare systems. • We need equitable supply and pricing models: wealthier countries can learn from approaches being used in healthcare systems with fewer resources • Adoption of new technologies remains slow: We must use cross-system learning to find the best, most practical solutions • We must rethink R&D: Antimicrobial drug development calls for fresh models leveraging genetics and machine learning, and novel trial designs to speed up the process • Diagnostics are critical to the response effort: We must improve access to diagnostics and communicate their value • Smarter clinical trials: Platform-trial designs could make AMR research more efficient and cost-effective • Simplifying the message: To engage policymakers and the public, complex science must be easily understandable, with a focus on hopeful, solution-driven narratives We're already looking forward to #GAMRIC2026! CARB-X ESCMID - European Society of Clinical Microbiology and Infectious Diseases Global Antibiotic R&D Partnership (GARDP) BEAM Alliance